Veru (NASDAQ:VERU) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Veru Inc. (NASDAQ:VERU)’s stock price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $2.53 and traded as low as $2.18. Veru shares last traded at $2.19, with a volume of 169,226 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Westpark Capital initiated coverage on Veru in a research report on Tuesday, October 6th. They set a “buy” rating for the company. Wall Street Zen cut Veru from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Veru in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

Veru Stock Performance

The stock has a market cap of $41.60 million, a price-to-earnings ratio of -3.54 and a beta of -1.21. The company’s 50 day simple moving average is $2.55 and its 200 day simple moving average is $2.53.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Sell-side analysts predict that Veru Inc. will post -1.07 EPS for the current year.

Institutional Investors Weigh In On Veru

A number of institutional investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in shares of Veru during the 2nd quarter valued at $328,000. Royal Bank of Canada lifted its holdings in shares of Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock valued at $27,000 after buying an additional 5,008 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Veru in the first quarter valued at $153,000. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.